Latest Licensing Deals News

Page 5 of 13
BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.
Ada Torres
Ada Torres
22 Dec 2025
Proteomics International has secured a US patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma, marking a critical step toward commercialisation in the world’s largest healthcare market.
Ada Torres
Ada Torres
17 Dec 2025
Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.
Ada Torres
Ada Torres
8 Dec 2025
Audeara Limited has secured its largest-ever Australian wholesale purchase order worth $560,000, driving year-to-date wholesale revenues to $1.75 million and matching full FY25 figures. The company is also expanding manufacturing into China, signaling growing international ambitions.
Ada Torres
Ada Torres
8 Dec 2025
Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.
Ada Torres
Ada Torres
4 Dec 2025
LaserBond’s 2025 AGM reveals a pivotal CEO transition alongside a strong financial rebound driven by strategic investments and technology licensing deals.
Victor Sage
Victor Sage
20 Nov 2025
AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.
Victor Sage
Victor Sage
20 Nov 2025
AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.
Victor Sage
Victor Sage
20 Nov 2025
FBR Limited has inked a non-binding Memorandum of Understanding with Fraser Lyne Constructions for the sale of a Hadrian® bricklaying robot unit valued at A$7.8 million, aiming to tackle New South Wales' housing shortage with advanced automation.
Sophie Babbage
Sophie Babbage
5 Nov 2025
Vectus Biosystems has signed a binding agreement to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its lead drug VB0004 and others, particularly in China.
Ada Torres
Ada Torres
30 Oct 2025
Temas Resources has completed its acquisition of ORF Technologies, gaining full ownership of the patented Regenerative Chloride Leach (RCL) technology that promises significant cost and environmental advantages in critical metals processing.
Maxwell Dee
Maxwell Dee
30 Oct 2025
Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.
Ada Torres
Ada Torres
29 Oct 2025